BETHESDA, MA — The US Food and Drug Administration (FDA) has approved edoxaban (Savaysa, Daiichi-Sankyo), a factor Xa inhibitor, for the prevention of stroke and non–central-nervous-system (CNS) systemic embolism in patients with nonvalvular atrial fibrillation (AF).
The FDA also approved edoxaban for treating deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5 to 10 days.
Nessun commento:
Posta un commento